Welcome to LookChem.com Sign In|Join Free

CAS

  • or
Stanolone, also known as Dihydrotestosterone (DHT), is a potent androgenic metabolite of testosterone. It is an endogenous androgen sex steroid and hormone that acts as an agonist of the androgen receptor (AR). Stanolone plays a crucial role in various physiological processes, including sexual differentiation, maturation of the penis and scrotum, hair and sebum production, and the development and maintenance of the prostate gland and seminal vesicles. It is a white crystalline solid and is regulated as a Schedule III compound in the United States.

521-18-6 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • High purity Dihydrotestosterone (commonly abbreviated to DHT), or 5α-dihydrotestosterone (5α-DHT) with high quality and best price cas:521-18-6

    Cas No: 521-18-6

  • USD $ 1.0-5.0 / Gram

  • 1 Gram

  • 99999 Kilogram/Year

  • Hangzhou Dingyan Chem Co., Ltd
  • Contact Supplier
  • 521-18-6 Structure
  • Basic information

    1. Product Name: Stanolone
    2. Synonyms: (5S,8R,9S,10S,13S,14S,17S)-17-Hydroxy-10,13-dimethyltetradecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one;5α-androstan-17β-ol-3-one solution,100ppm;(8R,9S,10S,13S,14S)-17-hydroxy-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one;(5-alpha,17-beta)-17-hydroxyandrostan-3-one;(5alpha,17beta)-17-Hydroxy-androstan-3-one;17beta-Hydroxy-3-androstanone;17-beta-hydroxy-5-alpha-androstan-3-on;17-hydroxy-,(5-alpha,17-beta)-androstan-3-on
    3. CAS NO:521-18-6
    4. Molecular Formula: C19H30O2
    5. Molecular Weight: 290.44
    6. EINECS: 208-307-3
    7. Product Categories: Steroids;Intermediates & Fine Chemicals;Pharmaceuticals;Steroid and Hormone;API
    8. Mol File: 521-18-6.mol
  • Chemical Properties

    1. Melting Point: 178-183 °C
    2. Boiling Point: 372.52°C (rough estimate)
    3. Flash Point: 9℃
    4. Appearance: /
    5. Density: 1.0320 (rough estimate)
    6. Vapor Pressure: 1.5E-08mmHg at 25°C
    7. Refractive Index: 1.4709 (estimate)
    8. Storage Temp.: Controlled Substance, -20°C Freezer
    9. Solubility: N/A
    10. PKA: 15.08±0.60(Predicted)
    11. Water Solubility: 344.3g/L(temperature not stated)
    12. Merck: 13,8872
    13. BRN: 2056371
    14. CAS DataBase Reference: Stanolone(CAS DataBase Reference)
    15. NIST Chemistry Reference: Stanolone(521-18-6)
    16. EPA Substance Registry System: Stanolone(521-18-6)
  • Safety Data

    1. Hazard Codes: Xn,T,F
    2. Statements: 61-40-39/23/24/25-23/24/25-11
    3. Safety Statements: 53-36/37/39-45-36/37-16
    4. RIDADR: UN1230 - class 3 - PG 2 - Methanol, solution
    5. WGK Germany: 3
    6. RTECS: BV8052000
    7. HazardClass: N/A
    8. PackingGroup: N/A
    9. Hazardous Substances Data: 521-18-6(Hazardous Substances Data)

521-18-6 Usage

Uses

Used in Medical Treatments:
Stanolone is used as a treatment for male hypogonadism, androgen deficiency of severe illness, androgen deficiency of aging, and microphallus in infancy. It helps in addressing the symptoms and complications associated with these conditions.
Used in Athletic Performance Enhancement:
Stanolone is used as an anabolic steroid to enhance physical performance in athletes. It is known for its powerful anabolic effects, which can lead to increased muscle mass and strength.
Used in Research and Forensic Applications:
As an analytical reference standard, Stanolone is used in research and forensic applications to study its properties and effects, as well as to detect its presence in various samples.
Used in the Treatment of Muscle Wasting Diseases and Osteoporosis:
Stanolone is used as a potent anabolic steroid for the treatment of muscle wasting diseases and osteoporosis. Its anabolic properties help in promoting muscle growth and maintaining bone density.
Used as a Controlled Substance:
Due to its potent androgenic effects, Stanolone is classified as a controlled substance, indicating its potential for misuse and the need for regulation in its production, distribution, and use.

Originator

Neodrol,Pfizer,US,1953

Manufacturing Process

A solution of 1.0 g of 3,17-androstandione in 50 ml of methanol and containing 1 g of selenium dioxide, was allowed to remain in an ice-chest overnight. The formed 3,3-dimethoxyandrostan-17-one was not separated. 1 g of solid potassium hydroxide and 2.5 g of sodium borohydride in 2.5 ml of water were added and the mixture allowed to react at room temperature for 24 hours. The solution was then poured into a large excess of water, extracted with methylene chloride, the organic layer dried and evaporated to a residue. The residue was dissolved in ether, and a small amount of selenium removed by filtration. The ether was boiled off and the organic material dissolved in 100 ml of boiling acetone. 25 ml of diluted hydrochloric acid were added, the solution boiled for 5 minutes and then allowed to cool. Upon crystallization, 0.85 g of androstan-17β-ol-3-one was obtained, melting point 175°C to 178°C.

Therapeutic Function

Androgen

References

https://en.wikipedia.org/wiki/Dihydrotestosterone#Medical_use Swerdloff, R. S., and C. Wang. "Dihydrotestosterone: a rationale for its use as a non-aromatizable androgen replacement therapeutic agent."Baillieres Clin Endocrinol Metab 12.3(1998):501.

Check Digit Verification of cas no

The CAS Registry Mumber 521-18-6 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 5,2 and 1 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 521-18:
(5*5)+(4*2)+(3*1)+(2*1)+(1*8)=46
46 % 10 = 6
So 521-18-6 is a valid CAS Registry Number.
InChI:InChI=1/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12,14-17,21H,3-11H2,1-2H3/t12?,14-,15-,16-,17-,18-,19-/m0/s1

521-18-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name 17β-hydroxy-5α-androstan-3-one

1.2 Other means of identification

Product number -
Other names [3H]-Dihydrotestosterone

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:521-18-6 SDS

521-18-6Synthetic route

17-((tert-butyldimethylsilyl)oxy)-10,13-dimethylhexadecahydro-3H-cyclopenta[a]phenanthren-3-one
58701-44-3

17-((tert-butyldimethylsilyl)oxy)-10,13-dimethylhexadecahydro-3H-cyclopenta[a]phenanthren-3-one

Stanolone
521-18-6

Stanolone

Conditions
ConditionsYield
With hydrogenchloride In ethanol at 20℃; for 3h;97.5%
(5S,8R,9S,10S,13S,14S,17S)-10,13-dimethylhexadecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dioxolan]-17-ol
1046-35-1

(5S,8R,9S,10S,13S,14S,17S)-10,13-dimethylhexadecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dioxolan]-17-ol

Stanolone
521-18-6

Stanolone

Conditions
ConditionsYield
With diiodosilane In chloroform at -42℃; for 0.166667h;95%
(5S,8R,9S,10S,13S,14S,17S)-17-(2-Methoxy-ethoxymethoxy)-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-3-one
91475-95-5

(5S,8R,9S,10S,13S,14S,17S)-17-(2-Methoxy-ethoxymethoxy)-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-3-one

Stanolone
521-18-6

Stanolone

Conditions
ConditionsYield
With chloro-trimethyl-silane; sodium iodide In acetonitrile at -20℃; for 0.75h;95%
5α-androstan-17β-ol-3-one tosylhydrazone
68199-33-7

5α-androstan-17β-ol-3-one tosylhydrazone

Stanolone
521-18-6

Stanolone

Conditions
ConditionsYield
With copper(II) sulfate In tetrahydrofuran; methanol; water for 17h; Heating;95%
17β-Hydroxy-5α-androstan-3-one 1,2-Ethanediyl Dithioacetal
37770-14-2

17β-Hydroxy-5α-androstan-3-one 1,2-Ethanediyl Dithioacetal

Stanolone
521-18-6

Stanolone

Conditions
ConditionsYield
With tri(p-bromophenyl)amine; lithium perchlorate; silica gel; sodium hydrogencarbonate In water; acetonitrile for 2h; electrolysis; further reagent: tris(4-bromophenyl)ammoniumyl hexachloroantimonate;91%
With tri(p-bromophenyl)amine; lithium perchlorate In water; acetonitrile Kinetics; Mechanism; cyclovoltammetry;
(5S,8R,9S,10S,13S,14S,17S)-10,13-Dimethyl-17-triethylsilanyloxy-hexadecahydro-cyclopenta[a]phenanthren-3-one
361336-13-2

(5S,8R,9S,10S,13S,14S,17S)-10,13-Dimethyl-17-triethylsilanyloxy-hexadecahydro-cyclopenta[a]phenanthren-3-one

Stanolone
521-18-6

Stanolone

Conditions
ConditionsYield
With polymer-bound NMe3(1+)*F(1-) In methanol at 20℃; for 24h;90%
C33H51NO4
75958-96-2

C33H51NO4

Stanolone
521-18-6

Stanolone

Conditions
ConditionsYield
With N,N,N',N'-tetramethyl-1,8-diaminonaphthalene In tetrahydrofuran Heating;88%
3-ethoxyandrost-3-ene-17-ol

3-ethoxyandrost-3-ene-17-ol

Stanolone
521-18-6

Stanolone

Conditions
ConditionsYield
With hydrogenchloride In ethanol; water at 60 - 65℃; Solvent; Reagent/catalyst;78%
methyl iodide
74-88-4

methyl iodide

A

Stanolone
521-18-6

Stanolone

B

17β-Hydroxy-4α-methyl-5α-androstan-3-on

17β-Hydroxy-4α-methyl-5α-androstan-3-on

C

4α-Methyl-17β-methoxy-5α-androstan-3-on

4α-Methyl-17β-methoxy-5α-androstan-3-on

D

2,4-Dimethyl-5α-dihydrotestoteron

2,4-Dimethyl-5α-dihydrotestoteron

Conditions
ConditionsYield
With lithium; isopropyl alcohol In tetrahydrofuran; diethyl ether; ammonia at -33℃; for 1.5h;A n/a
B 73%
C n/a
D n/a
C20H32O3

C20H32O3

Stanolone
521-18-6

Stanolone

Conditions
ConditionsYield
With 3-chloro-benzenecarboperoxoic acid In dichloromethane at 20℃;71%
3,17β-bis-<2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenoxy>-5α-androst-2-ene
112251-17-9

3,17β-bis-<2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenoxy>-5α-androst-2-ene

Stanolone
521-18-6

Stanolone

Conditions
ConditionsYield
With sodium methylate In N,N-dimethyl-formamide at 60℃; for 1h;58%
testosterone
58-22-0

testosterone

A

Stanolone
521-18-6

Stanolone

B

androstanedione
846-46-8

androstanedione

Conditions
ConditionsYield
biochem. proc. with 5α-reductase of Penicillin decumbens;A 10%
B 40%
With potato dextrose broth medium In ethanol at 24 - 26℃; for 96h; Penicillium decumbens ATCC 10436;A 28%
B 37%
testosterone
58-22-0

testosterone

A

Stanolone
521-18-6

Stanolone

B

5β-androstan-17β-ol-3-one
571-22-2

5β-androstan-17β-ol-3-one

Conditions
ConditionsYield
With palladium on activated charcoal; hydrogen In tetrahydrofuran at 20℃; for 6h;A n/a
B 39%
With hydrogen; palladium In pyridine at 25℃; under 760 Torr; Rate constant; selectivity to 5β compound;
With hydrogen bromide; hydrogen; palladium In tetrahydrofuran at 25℃; under 760 Torr; Rate constant; selectivity to 5β compound;
With 2,2'-azobis(isobutyronitrile); tributylzinc hydride In tetrahydrofuran for 1h; Heating; Yield given. Yields of byproduct given;
With hydrogen; palladium on activated charcoal In methanolA 54 % Chromat.
B 42 % Chromat.
5-androgen-3,17-diol
571-20-0

5-androgen-3,17-diol

A

Epiandrosterone
481-29-8

Epiandrosterone

B

Stanolone
521-18-6

Stanolone

C

androstanedione
846-46-8

androstanedione

Conditions
ConditionsYield
at 25℃; for 12h; electrolysis: nickel net anode, cylindrical stainless steel cathode; electrolyte: 0.01M KOH/t-butanol - water (1:1);A 3%
B 28%
C 30%
testosterone
58-22-0

testosterone

Stanolone
521-18-6

Stanolone

Conditions
ConditionsYield
With 5α-reductase from human prostate or liver; NADPH Equilibrium constant; Kinetics; Mechanism; Vmax, Km, var. of conc. of T, NADPH;
With 1,4-dioxane; diethyl ether; lithium Reagens 4:fluess.NH3;
With glucose-6-phosphate dehydrogenase; α-D-glucose 6-phosphate; NADP; human prostatic 5-α-reductase at 37℃; for 0.5h; Enzyme kinetics;
testosterone
58-22-0

testosterone

A

Stanolone
521-18-6

Stanolone

B

5-androgen-3,17-diol
571-20-0

5-androgen-3,17-diol

Conditions
ConditionsYield
With diethyl ether; palladium Hydrogenation;
androstanedione
846-46-8

androstanedione

Stanolone
521-18-6

Stanolone

Conditions
ConditionsYield
With methanol; selenium(IV) oxide anschliessend mit NaBH4 und KOH in H2O und Erwaermen des Reaktionsprodukts in Aceton mit wss.HCl;
Yield given. Multistep reaction;
Multi-step reaction with 3 steps
1: 83 percent / oxalic acid / Heating
2: NaBH4 / methanol / 1 h / 0 deg C to room temp.
3: 95 percent / diiodosilane / CHCl3 / 0.17 h / -42 °C
View Scheme
Multi-step reaction with 2 steps
1: benzene; ethanolic HCl / 75 °C
2: sodium; propanol-(1) / und Erwaermen des Reaktionsprodukts mit wss.-aethanol.HCl
View Scheme
With rabbit 3-hydroxyhexobarbital dehydrogenase (AKR1C29); NADPH In aq. phosphate buffer; ethyl acetate at 37℃; for 0.5h; pH=7.4; Catalytic behavior; Kinetics; Enzymatic reaction;
17β-hydroxy-5α-androstan-3-one-diethylacetal

17β-hydroxy-5α-androstan-3-one-diethylacetal

Stanolone
521-18-6

Stanolone

Conditions
ConditionsYield
With hydrogenchloride
3.3-diethoxy-5α-androstanone-(17)

3.3-diethoxy-5α-androstanone-(17)

Stanolone
521-18-6

Stanolone

Conditions
ConditionsYield
With propan-1-ol; sodium und Erwaermen des Reaktionsprodukts mit wss.-aethanol.HCl;
17β-hydroxy-5α-androstan-3-one semicarbazone
14045-84-2

17β-hydroxy-5α-androstan-3-one semicarbazone

Stanolone
521-18-6

Stanolone

Conditions
ConditionsYield
With sodium acetate; acetic acid; 2-oxo-propionic acid Regeneration;
5alpha-Androstane-3beta,17beta-diol-17-hexahydrobenzoate
20592-39-6

5alpha-Androstane-3beta,17beta-diol-17-hexahydrobenzoate

Stanolone
521-18-6

Stanolone

Conditions
ConditionsYield
With copper at 210℃; unter vermindertem Druck; und Erwaermen des Reaktionsprodukts mit methanol.Alkalilauge;
With chromium(VI) oxide; acetic acid und Erwaermen des Reaktionsprodukts mit methanol.Alkalilauge;
With aluminum tri-tert-butoxide; toluene; p-benzoquinone und Erwaermen des Reaktionsprodukts mit methanol.Alkalilauge;
testosterone
58-22-0

testosterone

A

Epiandrosterone
481-29-8

Epiandrosterone

B

Stanolone
521-18-6

Stanolone

C

cis-androsterone
53-41-8

cis-androsterone

D

androstanedione
846-46-8

androstanedione

E

5-androgen-3,17-diol
571-20-0

5-androgen-3,17-diol

F

androstanediol
1852-53-5

androstanediol

Conditions
ConditionsYield
With total testicular homogenate of adult Sprague-Dawley rats treated with 6, des-Gly-NH210>LHRH ethylamide Product distribution; metabolism, <3H>labelled study, further: equine antibovine LH serum (JOAN-5-31-67);
testosterone
58-22-0

testosterone

A

Stanolone
521-18-6

Stanolone

B

Androstenedione
63-05-8

Androstenedione

C

androstanedione
846-46-8

androstanedione

D

androstanediol
1852-53-5

androstanediol

Conditions
ConditionsYield
Product distribution; in vivo metabolism in epididymis of rats, influenced by estradiol-17β or cyproterone acetate, <3H>labeled study;
testosterone
58-22-0

testosterone

A

Stanolone
521-18-6

Stanolone

B

cis-androsterone
53-41-8

cis-androsterone

C

androstanedione
846-46-8

androstanedione

D

5-androgen-3,17-diol
571-20-0

5-androgen-3,17-diol

E

androstanediol
1852-53-5

androstanediol

Conditions
ConditionsYield
With carbon dioxide; 5α-reductase in testicular cells of adult male Sprague-Dawley rats; oxygen; NADP at 37℃; for 1.5h; Product distribution; Kinetics; <3H>labelled, metabolism with or without 7α-hydroxytestosterone;
testosterone
58-22-0

testosterone

A

Stanolone
521-18-6

Stanolone

B

5β-androstan-17β-ol-3-one
571-22-2

5β-androstan-17β-ol-3-one

C

5-androgen-3,17-diol
571-20-0

5-androgen-3,17-diol

D

4-androstenediol
1156-92-9

4-androstenediol

E

4-Androstene-3alpha,17beta-diol
1852-61-5

4-Androstene-3alpha,17beta-diol

Conditions
ConditionsYield
With H2SiEt2; Rh-(R,R)-(+)-DIOP for 24h; Product distribution; other reducing agents;
Conditions
ConditionsYield
With 7α-hydroxylase from microsomes of testicular tissue from Wistar rats injected or not intraperitoneally with human chorionic gonadotrophin till 24 h before kill; Krebs Ringer buffer; NADPH In ethanol at 37℃; for 0.25h; Product distribution; Kinetics; <4-14C>labeled study, Michaelis-Menton const. Km, maximal transformation rate Vm;
androstan-3-one
1224-95-9

androstan-3-one

Stanolone
521-18-6

Stanolone

Conditions
ConditionsYield
In water at 25℃; for 240h; biotransformation with cultures of Cephalosporium aphidicola (IMI 68689), other androstanones;70 mg
In ethanol; water at 25℃; for 240h; fermentation with cultures of Cephalosporium aphidicola (IMI 68689); Yield given;
Pregnenolone
145-13-1

Pregnenolone

A

testosterone
58-22-0

testosterone

B

Progesterone
57-83-0

Progesterone

C

Stanolone
521-18-6

Stanolone

D

dehydroepiandrosterone
53-43-0

dehydroepiandrosterone

E

Androstenedione
63-05-8

Androstenedione

Conditions
ConditionsYield
With human LH LER; isolated theca of LAK:LVG (SYR) hamsters at 37℃; for 2h; Product distribution; <3H>labeled, metabolism, var. of conc., time of incubation, preincubation, without LH;A 0.00094 mg
B 0.00006 mg
C 0.00017 mg
D 0.00026 mg
E 0.00030 mg
Androstenedione
63-05-8

Androstenedione

A

estradiol
50-28-2

estradiol

B

Estrone
53-16-7

Estrone

C

testosterone
58-22-0

testosterone

D

Stanolone
521-18-6

Stanolone

E

Etiocholanolone
53-42-9

Etiocholanolone

F

cis-androsterone
53-41-8

cis-androsterone

Conditions
ConditionsYield
With carcinoma; gynecomastia; mammary dysplasia at 37℃; for 1.5h; Product distribution; cofactors under 95percent O2: 5percent CO2, <3H>labeled study;
androstanedione
846-46-8

androstanedione

A

Epiandrosterone
481-29-8

Epiandrosterone

B

Stanolone
521-18-6

Stanolone

C

cis-androsterone
53-41-8

cis-androsterone

Conditions
ConditionsYield
With lithium aluminium tetrahydride; divinylbenzene template polymer In tetrahydrofuran Product distribution; Ambient temperature; other steroid ketones; molecular imprinting of solid polymer;
Stanolone
521-18-6

Stanolone

3-oxo-5α-androstan-17β-ol-3-18O
90991-89-2

3-oxo-5α-androstan-17β-ol-3-18O

Conditions
ConditionsYield
With hydrogenchloride; 18O-labeled water In 1,4-dioxane at 75℃; for 24h; sealed tube;100%
Stanolone
521-18-6

Stanolone

acryloyl chloride
814-68-6

acryloyl chloride

Acrylic acid (5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-3-oxo-hexadecahydro-cyclopenta[a]phenanthren-17-yl ester
27953-69-1

Acrylic acid (5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-3-oxo-hexadecahydro-cyclopenta[a]phenanthren-17-yl ester

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 1h;100%
With N-ethyl-N,N-diisopropylamine In dichloromethane at 0 - 20℃;100%
With triethylamine In chloroform at 25℃; for 0.25h;90%
Stanolone
521-18-6

Stanolone

ethane-1,2-dithiol
540-63-6

ethane-1,2-dithiol

17β-Hydroxy-5α-androstan-3-one 1,2-Ethanediyl Dithioacetal
37770-14-2

17β-Hydroxy-5α-androstan-3-one 1,2-Ethanediyl Dithioacetal

Conditions
ConditionsYield
With zeolite HSZ-360 In dichloromethane for 15h; Ambient temperature;100%
Stanolone
521-18-6

Stanolone

N-methoxylamine hydrochloride
593-56-6

N-methoxylamine hydrochloride

stanolone 3-Z,E-methyloxime

stanolone 3-Z,E-methyloxime

Conditions
ConditionsYield
With triethylamine; sodium hydroxide In tetrahydrofuran; water at 20 - 60℃; for 5h;100%
Stanolone
521-18-6

Stanolone

androstanedione
846-46-8

androstanedione

Conditions
ConditionsYield
With 4-methylmorpholine N-oxide; tetrapropylammonium perruthennate In dichloromethane for 1.5h; Ambient temperature;99%
With dipyridinium dichromate In dichloromethane at 20℃; for 2h; Inert atmosphere;99%
With N-chloro-succinimide; 4 A molecular sieve; potassium carbonate; N-(phenylthio)-N-(tert-butyl)amine In dichloromethane at 20℃; for 1h;96%
Stanolone
521-18-6

Stanolone

acetic anhydride
108-24-7

acetic anhydride

stanolone acetate
1164-91-6

stanolone acetate

Conditions
ConditionsYield
With pyridine; dmap at 20℃; for 6h; Inert atmosphere;99%
With pyridine; dmap at 20℃;
Stanolone
521-18-6

Stanolone

acetyl chloride
75-36-5

acetyl chloride

stanolone acetate
1164-91-6

stanolone acetate

Conditions
ConditionsYield
With pyridine In dichloromethane for 2h; Ambient temperature;98.3%
O-(2-hydroxyethyl)hydroxylamine
3279-95-6

O-(2-hydroxyethyl)hydroxylamine

Stanolone
521-18-6

Stanolone

(Z)-17β-hydroxy-5α-androstan-3-one O-(2-hydroxyethyl)oxime
130132-45-5, 130132-46-6

(Z)-17β-hydroxy-5α-androstan-3-one O-(2-hydroxyethyl)oxime

Conditions
ConditionsYield
With pyridine; acetic acid In ethanol for 0.5h; Heating;97%
Stanolone
521-18-6

Stanolone

tert-butyldimethylsilyl chloride
18162-48-6

tert-butyldimethylsilyl chloride

17-((tert-butyldimethylsilyl)oxy)-10,13-dimethylhexadecahydro-3H-cyclopenta[a]phenanthren-3-one
58701-44-3

17-((tert-butyldimethylsilyl)oxy)-10,13-dimethylhexadecahydro-3H-cyclopenta[a]phenanthren-3-one

Conditions
ConditionsYield
With 1H-imidazole In N,N-dimethyl-formamide Ambient temperature;97%
With 1H-imidazole In N,N-dimethyl-formamide at 20℃; silylation;91%
With 1H-imidazole In N,N-dimethyl-formamide at 20℃;91%
Stanolone
521-18-6

Stanolone

methyl 2-((tetrahydro-2H-pyran-2-yl)oxy)acetate
135643-82-2

methyl 2-((tetrahydro-2H-pyran-2-yl)oxy)acetate

(2α,5α,17β)-17-Hydroxy-2-<<(tetrahydro-2H-pyran-2-yl)oxy>acetyl>androstan-3-one
141507-29-1

(2α,5α,17β)-17-Hydroxy-2-<<(tetrahydro-2H-pyran-2-yl)oxy>acetyl>androstan-3-one

Conditions
ConditionsYield
With hydrogenchloride In N-methyl-acetamide; methanol96%
With sodium hydride 1) DMF, 1 h, rt, 2) DMF, 24 h; Yield given. Multistep reaction;
Stanolone
521-18-6

Stanolone

benzoyl chloride
98-88-4

benzoyl chloride

stanolone benzoate
1057-07-4

stanolone benzoate

Conditions
ConditionsYield
In pyridine at 60℃; for 2h;96%
Stanolone
521-18-6

Stanolone

tert-butylchlorodiphenylsilane
58479-61-1

tert-butylchlorodiphenylsilane

(5S,8R,9S,10S,13S,14S,17S)-17-[(tert-butyldiphenylsilyl)oxy]-10,13-dimethylhexadecahydro-3H-cyclopenta[a]phenanthren-3-one

(5S,8R,9S,10S,13S,14S,17S)-17-[(tert-butyldiphenylsilyl)oxy]-10,13-dimethylhexadecahydro-3H-cyclopenta[a]phenanthren-3-one

Conditions
ConditionsYield
With 1H-imidazole; dmap In dichloromethane at 20℃; for 5h;96%
Stanolone
521-18-6

Stanolone

ethylene glycol
107-21-1

ethylene glycol

(5S,8R,9S,10S,13S,14S,17S)-10,13-dimethylhexadecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dioxolan]-17-ol
1046-35-1

(5S,8R,9S,10S,13S,14S,17S)-10,13-dimethylhexadecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dioxolan]-17-ol

Conditions
ConditionsYield
With toluene-4-sulfonic acid In benzene for 3h; Heating;95%
With toluene-4-sulfonic acid In benzene for 24h; Heating;88%
With pyridine hydrochloride In toluene for 16h; Heating;84%
Stanolone
521-18-6

Stanolone

trisylhydrazine
39085-59-1

trisylhydrazine

17β-hydroxy-5α-androstan-3-one 2,4,6-tri-isopropylbenzenesulphonyl hydrazone
64055-14-7

17β-hydroxy-5α-androstan-3-one 2,4,6-tri-isopropylbenzenesulphonyl hydrazone

Conditions
ConditionsYield
In methanol at 20℃;94%
trifluoromethylsulfonic anhydride
358-23-6

trifluoromethylsulfonic anhydride

Stanolone
521-18-6

Stanolone

17β-triflate-5α-androstan-3-one
257619-83-3

17β-triflate-5α-androstan-3-one

Conditions
ConditionsYield
With pyridine In dichloromethane at 0℃; for 0.25h; Condensation;94%
Stanolone
521-18-6

Stanolone

bis-(2-methyl-1H-imidazol-1-yl)methanone
13551-83-2

bis-(2-methyl-1H-imidazol-1-yl)methanone

3-oxo-5α-androst-17β-yl-2'-methyl-1H-imidazole-1-carboxylate
1138159-97-3

3-oxo-5α-androst-17β-yl-2'-methyl-1H-imidazole-1-carboxylate

Conditions
ConditionsYield
In acetonitrile for 70h; Heating;94%
Stanolone
521-18-6

Stanolone

perfluorotoluene
434-64-0

perfluorotoluene

3,17β-bis-<2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenoxy>-5α-androst-2-ene
112251-17-9

3,17β-bis-<2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenoxy>-5α-androst-2-ene

Conditions
ConditionsYield
With cesium fluoride In N,N-dimethyl-formamide for 4h; Heating;93%
Stanolone
521-18-6

Stanolone

methyl chloroformate
79-22-1

methyl chloroformate

17β-methoxycarbonyloxy-5α-androstan-3-one
19291-29-3

17β-methoxycarbonyloxy-5α-androstan-3-one

Conditions
ConditionsYield
In pyridine at 0℃; for 24h;92%
Stanolone
521-18-6

Stanolone

2,3-Dipyridin-2-ylquinoxaline-6-carboxylic acid
17401-74-0

2,3-Dipyridin-2-ylquinoxaline-6-carboxylic acid

17β-(Ol-2,3-bipyridin-2-ylquinoxaline-6-carboxylate)-5α-androstan-3-one

17β-(Ol-2,3-bipyridin-2-ylquinoxaline-6-carboxylate)-5α-androstan-3-one

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In dichloromethane at 20℃; for 24h;92%
Stanolone
521-18-6

Stanolone

8-(2-aminoethyl)-2,3,4,5-tetrahydro-1H,4H-11-oxa-3a-aza-benzo-[de]anthracen-10-one hydrochloride

8-(2-aminoethyl)-2,3,4,5-tetrahydro-1H,4H-11-oxa-3a-aza-benzo-[de]anthracen-10-one hydrochloride

(3R,5S,10S,13S,17S)-17-hydroxy-10,13-dimethyl-1,2,2',3',4,5,6,7,8,8',9,9',1',11,12,12',13,13',14,15,16,17-docosahydro-7'H,11'H-spiro[cyclopenta[a]phenanthrene-3,4'-pyrido[3,2,1-ij]pyrido[4',3':4,5]pyrano[2,3-f ]quinolin]-5'(1'H)-one hydrochloride

(3R,5S,10S,13S,17S)-17-hydroxy-10,13-dimethyl-1,2,2',3',4,5,6,7,8,8',9,9',1',11,12,12',13,13',14,15,16,17-docosahydro-7'H,11'H-spiro[cyclopenta[a]phenanthrene-3,4'-pyrido[3,2,1-ij]pyrido[4',3':4,5]pyrano[2,3-f ]quinolin]-5'(1'H)-one hydrochloride

Conditions
ConditionsYield
With hydrogenchloride In ethanol for 48h; Pictet-Spengler Synthesis; Reflux; Sealed tube;92%
With hydrogenchloride In ethanol for 24h; Sealed tube; Reflux;
Stanolone
521-18-6

Stanolone

benzaldehyde
100-52-7

benzaldehyde

17β-hydroxy-2-benzylidene-5-androstan-3-one

17β-hydroxy-2-benzylidene-5-androstan-3-one

Conditions
ConditionsYield
With potassium hydroxide In ethanol at 20℃; for 3h; Temperature; Claisen-Schmidt Condensation; regioselective reaction;92%
Stanolone
521-18-6

Stanolone

(2Z)-2-methyl-2-butenoic 2,4,6-trichlorobenzoic anhydride
137601-32-2

(2Z)-2-methyl-2-butenoic 2,4,6-trichlorobenzoic anhydride

Angelate Ester of 5α-androstan-17β-ol-3-one
137601-35-5

Angelate Ester of 5α-androstan-17β-ol-3-one

Conditions
ConditionsYield
In toluene at 70℃; for 23h;91%
Stanolone
521-18-6

Stanolone

(5R,8R,9S,10S,13S,14S,17S)-10,13-Dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-ol
1225-43-0

(5R,8R,9S,10S,13S,14S,17S)-10,13-Dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-ol

Conditions
ConditionsYield
With acetic acid; zinc In water at 20℃; for 12h;91%
With zinc In acetic acid at 15℃; for 0.25h; ultrasonic irradiation;90%
With hydrazine hydrate; potassium hydroxide In diethylene glycol at 200 - 220℃; for 16h;86%
With acetic acid; zinc In water at 20℃; for 16h;
Stanolone
521-18-6

Stanolone

4-fluorobenzaldehyde
459-57-4

4-fluorobenzaldehyde

17β-hydroxy-2-(4-fluoro)benzylidene-5-androstan-3-one

17β-hydroxy-2-(4-fluoro)benzylidene-5-androstan-3-one

Conditions
ConditionsYield
With potassium hydroxide In ethanol at 20℃; for 3h; Claisen-Schmidt Condensation; regioselective reaction;91%
Stanolone
521-18-6

Stanolone

N,N-dimethyl-formamide
68-12-2, 33513-42-7

N,N-dimethyl-formamide

3-oxo-5α-androstan-17β-yl formate
4589-90-6

3-oxo-5α-androstan-17β-yl formate

Conditions
ConditionsYield
With diphenylphosphinopolystyrene; iodine In dichloromethane at 0℃; for 1h;90%

521-18-6Relevant articles and documents

A kinetic analysis of the 5α-reductases from human prostate and liver

Houston,Chisholm,Habib

, p. 355 - 369 (1987)

A kinetic analysis of the 5α-reductases from human liver and prostate is presented. Human prostatic 5α-reductase follows an ordered sequential mechanism in which NADPh binds first followed by testosterone. The order of release of products is DHT followed by NADP+. The apparent K(m) of prostatic 5α-reductase for testosterone is 0.0339 ± 0.006μM, while the apparent K(m) for NADPh is 2.52 ± 0.65μM. Human liver 5α-reductase also follows a sequential mechanism. The apparent K(m) of the liver enzyme is 0.110 ± 0.08μM; the apparent K(m) for NADPH is 6.2 ± 0.6μM. The fact that both the liver and prostatic 5α-reductases have a sequential kinetic mechanism rules out the possibility that the reduction of testosterone to dihydrotestosterone involves an electron transport system as previously proposed.

Comparative study of human steroid 5α-reductase isoforms in prostate and female breast skin tissues: Sensitivity to inhibition by finasteride and epristeride

Ranjan, Mala,Diffley, Penny,Stephen, Gita,Price, David,Walton, Terence J.,Newton, Russell P.

, p. 115 - 126 (2002)

Steroid 5α-reductase (5-AR) catalyses the reduction of testosterone (T) to dihydrotestosterone (DHT). The 5α-reductase found in human benign prostatic hyperplasia (BPH) has been compared with that found in human breast skin tissue in respect of sensitivity to inhibition by Finasteride and Epristeride. Kinetic studies showed the presence of two isoforms of 5α-reductase in benign prostatic hyperplasia indicated by low and high Km isoforms for testosterone, while female breast skin tissue contained only one isoform. The isoforms differ in their affinity for the inhibitors Finasteride and Epristeride, both compounds being more effective for the low Km 5α-reductase isoform than the high Km 5α-reductase of prostatic tissue, with Finasteride displaying competitive inhibition and Epristeride uncompetitive. Finasteride and Epristeride are also inhibitors of skin 5α-reductase, which possesses a comparable Ki for Finasteride to that of the low Km prostatic enzyme, but Epristeride was a less potent inhibitor of the skin enzyme relative to the prostate isoform. These results suggest that the inhibitors have therapeutic potential, other than for treatment of benign prostatic hyperplasia, for treating skin disorders influenced by the action of dihydrotestosterone and warrant further investigation.

Stereochemistry of Reduction by the 5α-Reductase Enzyme of Penicillium decumbens and the 1H NMR Assignment of 5α-Dihydrotestosterone

Holland, Herbert L.,Xu, Weili,Hughes, Donald W.

, p. 1760 - 1761 (1989)

Reduction of the alkenic bond of testosterone and androst-4-ene-3,7-dione by the 5α-reductase enzyme of Penicillium decumbens with trans stereochemistry.

Significance of the delta 5 and delta 4 steroidogenic pathways in the hamster preovulatory follicle.

Makris,Olsen,Ryan

, p. 641 - 651 (1983)

Isolated hamster granulosa cells and theca from preovulatory follicles were incubated in vitro for 2 and 6 h in the absence/or presence of LH and steroid substrates. The purpose of the experiments was to determine, in theca, the relative activities of the delta 5 and delta 4 pathways under controlled conditions, and to compare the ability of granulosa cells and theca to form progesterone from exogenous pregnenolone. The results of the experiments show that the delta 5 pathway in theca predominates before and up to 2 h after LH stimulation. The delayed effect of LH after 2 h is a switch from delta 5 to delta 4 as the major metabolic pathway. Progesterone formation from exogenous pregnenolone is 7 to 10 times greater in unstimulated granulosa cells than in theca. Acute effects of LH lead to increased conversion of exogenous pregnenolone to progesterone in granulosa cells but not theca. LH does, however, acutely stimulate the thecal conversion of DHEA to androstenedione. The longer term effect of LH in both cell types is to increase pregnenolone conversion to progesterone.

Spatial Localization and Quantitation of Androgens in Mouse Testis by Mass Spectrometry Imaging

Cobice, Diego F.,Livingstone, Dawn E. W.,MacKay, C. Logan,Goodwin, Richard J. A.,Smith, Lee B.,Walker, Brian R.,Andrew, Ruth

, p. 10362 - 10367 (2016)

Androgens are essential for male development and reproductive function. They are transported to their site of action as blood-borne endocrine hormones but can also be produced within tissues to act in intracrine and paracrine fashions. Because of this, circulating concentrations may not accurately reflect the androgenic influence within specific tissue microenvironments. Mass spectrometry imaging permits regional analysis of small molecular species directly from tissue surfaces. However, due to poor ionization and localized ion suppression, steroid hormones are difficult to detect. Here, derivatization with Girard T reagent was used to charge-tag testosterone and 5α-dihydrotestosterone allowing direct detection of these steroids in mouse testes, in both basal and maximally stimulated states, and in rat prostate. Limits of detection were ~0.1 pg for testosterone. Exemplary detection of endogenous steroids was achieved by matrix-assisted laser desorption ionization and either Fourier transform ion cyclotron resonance detection (at 150 μm spatial resolution) or quadrupole-time-of-flight detection (at 50 μm spatial resolution). Structural confirmation was achieved by collision induced fragmentation following liquid extraction surface analysis and electrospray ionization. This application broadens the scope for derivatization strategies on tissue surfaces to elucidate local endocrine signaling in health and disease.

Synthetic method of androstenone

-

Paragraph 0087-0089; 0097-0099; 0102-0104; 0107-0109, (2021/05/12)

The invention relates to the field of medicine preparation, in particular to a synthetic method of androstenone. The preparation method comprises the following steps: S100, catalyzing testosterone by a catalyst, and carrying out hydrogenation addition reaction to obtain a compound I; S200, converting a 17-site hydroxyl group of the compound I into a halogen group or a sulfonate group which is easy to leave, so as to obtain a compound II; and S300, subjecting the compound II and alkali to an elimination reaction under the heating condition, namely, a dehalogenation reaction or a desulphonate reaction, so as to obtain androstenone. The synthesis method of androsteneone has the following beneficial effects: the raw materials are cheap and easy to obtain; the process is simple, the route is short, and the requirement on equipment is low; dangerous reagents and operation are avoided, and large-scale industrial production is easy to realize; and isomer impurities are not generated in the synthesis process, and the yield of the target product androsteneone is high.

Formation of 5α-dihydrotestosterone from 5α-androstane-3α,17β-diol in prostate cancer LAPC-4 cells – Identifying inhibitors of non-classical pathways producing the most potent androgen

Boutin, Sophie,Roy, Jenny,Maltais, René,Poirier, Donald

supporting information, (2019/11/26)

5α-Dihydrotestosterone (5α-DHT) possesses a great affinity for the androgen receptor (AR), and its binding to AR promotes the proliferation of prostate cancer (PC) cells in androgen-dependent PC. Primarily synthesized from testosterone (T) in testis, 5α-DHT could also be produced from 5α-androstane-3α,17β-diol (3α-diol), an almost inactive androgen, following non-classical pathways. We reported the chemical synthesis of non-commercially available [4-14C]-3α-diol from [4-14C]-T, and the development of a biological assay to identify inhibitors of the 5α-DHT formation from radiolabeled 3α-diol in LAPC-4 cell PC model. We measured the inhibitory potency of 5α-androstane derivatives against the formation of 5α-DHT, and inhibition curves were obtained for the most potent compounds (IC50 = 1.2–14.1 μM). The most potent inhibitor 25 (IC50 = 1.2 μM) possesses a 4-(4-CF3-3-CH3O-benzyl)piperazinyl methyl side chain at C3β and 17β-OH/17α-C[tbnd]CH functionalities at C17 of a 5α-androstane core.

The A-ring reduction of 11-ketotestosterone is efficiently catalysed by AKR1D1 and SRD5A2 but not SRD5A1

Barnard, Lise,Nikolaou, Nikolaos,Louw, Carla,Schiffer, Lina,Gibson, Hylton,Gilligan, Lorna C.,Gangitano, Elena,Snoep, Jacky,Arlt, Wiebke,Tomlinson, Jeremy W.,Storbeck, Karl-Heinz

, (2020/07/21)

Testosterone and its 5α-reduced form, 5α-dihydrotestosterone, were previously thought to represent the only active androgens in humans. However, recent studies have shown that the potent androgen, 11-ketotestosterone, derived from the adrenal androgen precursor, 11β-hydroxyandrostenedione, may in fact serve as the primary androgen in healthy women. Yet, despite recent renewed interest in these steroids, their downstream metabolism has remained undetermined. We therefore set out to investigate the metabolism of 11-ketotestosterone by characterising the 5α- or 5β-reduction commitment step. We show that inactivation of 11-ketotestosterone is predominantly driven by AKR1D1, which efficiently catalyses the 5β-reduction of 11-ketotestosterone, committing it to a metabolic pathway that terminates in 11-ketoetiocholanolone. We demonstrate that 5α-reduction of 11-ketotestosterone is catalysed by SRD5A2, but not SRD5A1, and terminates in 11-ketoandrosterone, but is only responsible for a minority of 11-ketotestosterone inactivation. However, as 11-ketoetiocholanolone is also generated by the metabolism of the glucocorticoid cortisone, 11-ketoandrosterone should be considered a more specific urinary marker of 11-ketotestosterone production.

Mild Deprotection of Dithioacetals by TMSCl/NaI Association in CH3CN

Yao, Yunxin,Zhao, Guangkuan,Hamze, Abdallah,Alami, Mouad,Provot, Olivier

, p. 5775 - 5779 (2020/08/17)

A mild process using a combination of TMSCl and NaI in acetonitrile is used to regenerate carbonyl compounds from a variety of dithiane and dithiolane derivatives. This easy to handle and inexpensive protocol is also efficient to deprotect oxygenated and mixed acetals as 1,3-dioxanes, 1,3-dioxolanes and 1,3-oxathianes quantitatively. As a possible extension of this method, it was also shown that nitrogenated substrates such as hydrazones, N-tosylhydrazones, and ketimines reacted well under these conditions to give the expected ketones in high yields. The methodology proposed herein is a good alternative to the existing methods since it does not use metals, oxidants, reducing agents, acidic or basic media, and keto-products were obtained in high to excellent yields.

Purified mCPBA, a Useful Reagent for the Oxidation of Aldehydes

Horn, Alexander,Kazmaier, Uli

, p. 2531 - 2536 (2018/03/21)

Purified mCPBA is a useful reagent for the oxidation of several classes of aldehyde. Although linear unbranched aliphatic aldehydes are oxidized to the corresponding carboxylic acids, α-branched ones undergo Baeyer–Villiger oxidation to formates. α-Branched α,β-unsaturated aldehydes provide enolformates and/or epoxides, which can be saponified to α-hydroxy ketones with shortening of the carbon chain by 1 carbon. Unbranched α,β-unsaturated aldehydes undergo an interesting Baeyer–Villiger oxidation/epoxidation/formate migration/BV oxidation cascade, which results in formyl-protected hydrates with an overall loss of two carbon atoms.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 521-18-6